NeuroOne Medical Technologies Corporation Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
NeuroOne Medical Technologies Corporation (NMTC) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $1.78 million as of 2023-12-30, per its 10-K filed 2023-12-15.
Discontinued › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2023-12-15
- 2023-12-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.78M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2023-12-30 | $1.78M 10-K · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B |